Blog Archive

New Services: Strategic Statistical Support

Facet’s new Strategic Statistical Services group uses statistical principles and methodologies to maximize precision and efficiency in the development of drugs, biologics, medical devices, and combination products.  More and mo...

Read More

FDA Round Up – Q4 2023

FDA ROUNDUP: New FDA guidance: Stimulant Use Disorders:  Developing Drugs for Treatment (Draft October 2023) – The purpose of this guidance is to provide Sponsors with recommendations on clinical development of drugs for ...

Read More

Did You Know – Q4 2023

DID YOU KNOW? Facet’s strategic and tactical regulatory affairs, statistics, regulatory writing, and commercialization experts lead small organizations to faster and more efficient product development, US registration, and com...

Read More

Facet By The Numbers – Q3 2023

FACET BY THE NUMBERS Total submissions to FDA July – Sept 2023:  over 40 (over 3 submissions a week!) Early-stage development highlights: prepared/submitted 2 INDs for new chemical entities and over 30 IND amendments (e.g., new...

Read More

Did You Know – Q3 2023

DID YOU KNOW? Facet is on a mission to help small organizations bring great science and innovative products to and through FDA. Many small organizations waste significant money and time running large nonclinical programs to su...

Read More
Go to Top